Table 2. Diagnostic performance of gFOBT, iFOBT and blood-based inflammatory markers: sensitivities and specificities for detection of advanced adenoma and colorectal cancer (CRC).
|
Sensitivity % (95% CI)
|
||||
|---|---|---|---|---|
| Test | Cut point (ng ml −1) | Advanced adenoma ( n=183) | CRC ( n=67) | Specificity % (95% CI) |
| gFOBT | — | 7.7 (4.6–12.4) | 40.3 (29.4–52.3) | 97.7 (94.7–99.0) |
| CRP | 2499.9 | 4.9 (2.6–9.1) | 19.4 (11.7–30.4) | 90.3 (85.7–93.6) |
| sCD26 | 133.5 | 4.4 (2.2–8.4) | 0 (0–5.4) | 97.2 (94.1–98.7) |
| TIMP-1 | 928.2 | 7.1 (4.2–11.8) | 13.4 (7.2–26.6) | 97.7 (94.7–99.0) |
| iFOBT | 24.0a | 19.7 (14.6–26.0) | 65.7 (53.7–75.9) | 97.7 (94.7–99.0) |
Abbreviations: CI=confidence interval; CRP=C-reactive protein; gFOBT=guaiac-based faecal occult blood test; iFOBT=immunochemical faecal occult blood test; sCD26=serum CD26; TIMP-1=tissue inhibitor of metalloproteinases 1.
a
μg per gram stool.